Mark Lackner - Feb 3, 2025 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Scientific Officer
Signature
/s/ Andrea Paul, attorney-in-fact for Mark Lackner
Stock symbol
ZNTL
Transactions as of
Feb 3, 2025
Transactions value $
-$24,591
Form type
4
Date filed
2/5/2025, 06:32 PM
Previous filing
Jan 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +336K +175.58% $0.00 527K Feb 3, 2025 Direct F1
transaction ZNTL Common Stock Sale -$24.6K -14.4K -2.73% $1.71 513K Feb 3, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +125K $0.00 125K Feb 3, 2025 Common Stock 125K $1.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
F2 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
F3 The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.